This study is currently not recruiting participants.

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Study of an Investigational mRNA Vaccine for Respiratory Syncytial Virus and Human Metapneumovirus

Not Recruiting
18 years or above
All
Phase 1
558 participants needed

Study Overview

The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older.

Treatment
  • RSV/hMPV mRNA / LNP 1 at 3-4 different doses or,
  • RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or,
  • RSV mRNA / LNP 1 at 1 dose or,
  • hMPV mRNA / LNP 1 at 1 dose

Study Details

Study duration per participant is approximately 6 months.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

-Informed consent form (ICF) has been signed and dated

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

-Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.

--The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

This study investigates the prevention of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) using an investigational mRNA vaccine. Participants will receive a vaccine for preventing lower respiratory tract disease caused by these viruses.

The purpose of this study is to evaluate the safety and immune response of the investigational mRNA vaccine. The study focuses on understanding how the vaccine impacts the body's immune system in adults aged 18 to 49 and 60 years and older.

  • Who can participate: Participants aged 18 to 49 years and 60 years and older who are healthy and able to provide informed consent can join the study.
  • Study details: Participants will receive a single intramuscular injection of the investigational mRNA vaccine at different doses.
  • Study timelines: The study will last approximately 6 months per participant.
Updated on 11 Sep 2025. Study ID: NCT06237296